COVID-SEROINDEX
DEAD

Serial Number

90089929

Owner

Kantaro Biosciences LLC

Attorney

Michelle A. Cooke

Filing Date

Aug 3, 2020

Add to watchlist:

No watchlists yet
View on USPTO

COVID-SEROINDEX Trademark

Serial Number: 90089929

COVID-SEROINDEX is a trademark filed by Kantaro Biosciences LLC on August 3, 2020. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

Kantaro Biosciences LLC (13 trademarks)

1460 Broadway
New York, NY 10036

Entity Type: 16

Trademark Details

Filing Date

August 3, 2020

Registration Date

Not Registered

Published for Opposition

July 5, 2022

Goods & Services

Diagnostic agents, preparations and substances for medical or veterinary purposes; Medical diagnostic reagents and assays for testing and analysis of blood, bodily fluids, biological and cellular samples and specimens; Reagents for medical use; Clinical medical reagents; Diagnostic assays, reagents, media, solutions and buffers for medical use; Diagnostic agents for carrying out serologic tests for medical purposes; Diagnostic reagents for serologic tests of infections for medical purposes; Diagnostic agents, preparations, substances and diagnostic test kits used for detecting antibodies, enzymes, antigens, diseases, viruses and infections for medical purposes; Test kits consisting of medical diagnostic reagents, assays, solutions and buffers for testing in the field of the prevention and treatment of infections, viruses, disorders and diseases; Diagnostic kits comprised of medical diagnostic reagents and assays for testing and analysis of blood, bodily fluids, biological and cellular samples and specimens for use in infection, virus and disease detection, namely, infectious, viral, communicable, blood-borne pathogen, vector-borne, pulmonary, respiratory, inflammatory, immunological, autoimmune, rheumatic and cardiovascular diseases and disorders; Diagnostic preparations for medical purposes for detecting the presence of infectious, viral, communicable, blood-borne pathogen, vector-borne, pulmonary, respiratory, inflammatory, immunological, autoimmune, rheumatic and cardiovascular diseases and disorders; Medicated, therapeutic and pharmaceutical preparations and substances for the prevention and treatment of SARS-CoV-2, COVID-19, and infectious, viral, communicable, blood-borne pathogen, vector-borne, pulmonary, respiratory, inflammatory, immunological, autoimmune, rheumatic and cardiovascular diseases and disorders; Specimen collection kits for use in medical and clinical testing for the presence of antibodies in blood, biological fluids, bodily fluids, biological and cellular samples and specimens and tissue comprised primarily of assays, reagents, media, solutions, buffers, antibodies, antigens, control materials, membranes, plasma, diagnostic chemicals, calibrators, swabs for medical purposes, plates, vessels, tubes, pipettes, trays, panels, slides, cards and bottles; all the foregoing related to the detection, diagnosis, testing, prevention and/or treatment of SARS-CoV-2, COVID-19 and antibodies, antigens, diseases, illnesses, viruses, disorders and/or infections related to SARS-CoV-2 or COVID-19

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Apr 3, 2023 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Apr 3, 2023 ABN6
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Aug 30, 2022 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 5, 2022 NPUB
PUBLISHED FOR OPPOSITION
Jul 5, 2022 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 15, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 31, 2022 CNSA
EXAMINER'S AMENDMENT ENTERED
May 31, 2022 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
May 31, 2022 GNEN
EXAMINERS AMENDMENT E-MAILED
May 31, 2022 GNEA
EXAMINERS AMENDMENT -WRITTEN
May 31, 2022 CNEA
NOTIFICATION OF FINAL REFUSAL EMAILED
Nov 14, 2021 GNFN
FINAL REFUSAL E-MAILED
Nov 14, 2021 GNFR
FINAL REFUSAL WRITTEN
Nov 14, 2021 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 27, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 26, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 26, 2021 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 20, 2021 GNRN
NON-FINAL ACTION E-MAILED
Mar 20, 2021 GNRT
NON-FINAL ACTION WRITTEN
Mar 20, 2021 CNRT
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 26, 2021 GNRN
NON-FINAL ACTION E-MAILED
Feb 26, 2021 GNRT
NON-FINAL ACTION WRITTEN
Feb 26, 2021 CNRT
ASSIGNED TO EXAMINER
Feb 10, 2021 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 1, 2020 NWOS
NEW APPLICATION ENTERED
Aug 6, 2020 NWAP